Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
731 Leser
Artikel bewerten:
(2)

NEVCORE Innovations: CLEW Modern Oral Nicotine Pouches Receive FDA Acceptance For Premarket Tobacco Product Application (PMTA)

KENT, Del., June 6, 2024 /PRNewswire/ -- Nevcore Innovations Inc. ("Nevcore Innovations") is proud to announce the acceptance of its Premarket Tobacco Product Application (PMTA) submission by the U.S. Food and Drug Administration for its brand, CLEW modern oral nicotine pouches. As one of the very few brands to achieve this feat, this latest announcement solidifies the brand's position as a groundbreaking offering and is a leap forward in innovation, offering a discreet, smoke-free, and hassle-free alternative for adult nicotine consumers.

Formulated at the top labs in the USA, and manufactured in state-of-the-art cGMP and HAACP certified facilities, CLEW modern oral nicotine pouches will be available in a range of flavors to suit every palate and strengths of 3mg, 5mg, 6mg, 9mg, 10mg, 12mg, 15mg and 20mg, ensuring there's something for everyone to enjoy. From refreshing mint and fruit, as well as classic tobacco flavors, CLEW offers a diverse selection that caters to a wide range of tastes.

Speaking at the occasion, Mr. Nutesh Singla, Founder & Chairman of Nevcore Innovations, emphasised:
"At the core of CLEW lies our unwavering commitment to delivering an unparalleled experience, by blending cutting-edge technology with the finest ingredients. Crafted with precision and passion, CLEW nicotine pouches are formulated at the top laboratories in the USA and contain pharmaceutical-grade nicotine and carefully selected flavorings, ensuring a gratifying sensation with every use."

Designed for convenience and discretion, CLEW pouches are small and portable, making them ideal for use in any setting, whether at work, on-the-go, or in the comfort of one's home. With CLEW, consumers can enjoy their nicotine fix without smoke or vapor, offering a cleaner and more refined experience.

Mr. Waqas Khan, Global CEO at Nevcore Innovations, said:
"CLEW nicotine pouches herald a new era in nicotine indulgence, and we are confident they will set the new global benchmark for white nicotine pouches the world over. We have listened to the needs and desires of consumers and have developed a product that not only meets but exceeds their expectations and are confident that they will play a significant role in global harm reduction efforts. With CLEW, we are reimagining what it means to enjoy nicotine, providing a solution that is both convenient and satisfying."

CLEW nicotine pouches will be available in a range of flavors to suit every palate and strengths of 3mg, 5mg, 6mg, 9mg, 10mg, 12mg, 15mg and 20mg, ensuring there's something for everyone to enjoy. From refreshing mint and fruit, as well as classic tobacco flavors, CLEW offers a diverse selection that caters to a wide range of tastes.

Keeping in line with global transparency and responsibility standards, CLEW pouches are manufactured in state-of-the-art cGMP and HAACP certified facilities that maintain rigorous compliance with the strictest quality protocols and ensure products meet the highest safety standards. Additionally, CLEW is intended for use by adult consumers only and is not recommended for non-smokers or individuals under the legal smoking age.

About Nevcore Innovations Inc.

NEVCORE Innovations is a leading global manufacturer of premium-quality next-generation products. We specialize in modern oral nicotine pouches, vaping disposables, and energy pouches. Our mission is to be at the forefront of nicotine harm reduction, inspiring future generations with exceptional offerings and fostering a smoke-free world where indulgence meets responsibility.

Photo - https://mma.prnewswire.com/media/2431717/NEVCORE_Innovations_CLEW_Modern_Oral_Nicotine_Pouches_Receive_FD.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/clew-modern-oral-nicotine-pouches-receive-fda-acceptance-for-premarket-tobacco-product-application-pmta-302166241.html

© 2024 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.